US 12,305,206 B2
Methods for making L-glufosinate
Brian Michael Green, Lutherville, MD (US); and Michelle Lorraine Gradley, Canterbury (GB)
Assigned to BASF SE, Ludwigshafen (DE)
Filed by BASF SE, Ludwigshafen (DE)
Filed on Feb. 7, 2024, as Appl. No. 18/435,340.
Application 15/787,448 is a division of application No. 15/445,254, filed on Feb. 28, 2017, granted, now 9,834,802, issued on Dec. 5, 2017.
Application 18/435,340 is a continuation of application No. 18/179,136, filed on Mar. 6, 2023, granted, now 11,913,048.
Application 18/179,136 is a continuation of application No. 17/530,018, filed on Nov. 18, 2021, granted, now 11,905,538.
Application 17/530,018 is a continuation of application No. 16/997,133, filed on Aug. 19, 2020, granted, now 11,560,577, issued on Jan. 24, 2023.
Application 16/997,133 is a continuation of application No. 16/287,290, filed on Feb. 27, 2019, granted, now 10,781,465, issued on Sep. 22, 2020.
Application 16/287,290 is a continuation of application No. 15/787,448, filed on Oct. 18, 2017, granted, now 10,260,078, issued on Apr. 16, 2019.
Claims priority of provisional application 62/413,240, filed on Oct. 26, 2016.
Claims priority of provisional application 62/336,989, filed on May 16, 2016.
Claims priority of provisional application 62/302,421, filed on Mar. 2, 2016.
Prior Publication US 2024/0309409 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 13/02 (2006.01); A01N 25/30 (2006.01); A01N 57/20 (2006.01); C12N 1/20 (2006.01); C12N 9/10 (2006.01); C12P 9/00 (2006.01); C12P 13/04 (2006.01); C12P 41/00 (2006.01)
CPC C12P 13/02 (2013.01) [A01N 25/30 (2013.01); A01N 57/20 (2013.01); C12N 1/20 (2013.01); C12N 9/10 (2013.01); C12P 9/00 (2013.01); C12P 13/04 (2013.01); C12P 41/00 (2013.01); C12Y 104/03003 (2013.01); C12Y 206/01019 (2013.01)] 6 Claims
 
1. A formulation comprising:
L-glufosinate ammonium in an amount from 10-30% by weight of the formulation and D-glufosinate, wherein the formulation has greater than about 90% L-glufosinate compared to the sum of the D-glufosinate and the L-glufosinate present in the formulation;
one or more additional components selected from the group consisting of:
sodium alkyl ether sulfate in an amount from 10-40% by weight of the formulation;
1-methoxy-2-propanol in an amount from 0.5-2% by weight of the formulation;
dipropylene glycol in an amount from 4-18% by weight of the formulation;
alkyl polysaccharide in an amount from 4-20% by weight of the formulation; and
water as the balance of the formulation.